Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Neoplasms 5Vipoma 4Carcinoma, Islet Cell 4Somatostatinoma 3Neuroendocrine Tumors 3Intestinal Obstruction 3Insulinoma 3Glucagonoma 3Gastrinoma 3Carcinoma, Hepatocellular 3Thymoma 2Stomach Neoplasms 2Prostatic Neoplasms 2Neoplasm Metastasis 2Meningioma 2Diarrhea 2Carcinoma 2Carcinoid Tumor 2Adenoma, Islet Cell 2Weight Loss 1Waldenstrom Macroglobulinemia 1Vomiting 1Recurrence 1Rectal Neoplasms 1Primary Inoperable Thymoma 1Pleural Effusion 1Pheochromocytoma 1Peritoneal Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1

Interventions

Prednisone 3pembrolizumab 2Melphalan 2Cytarabine 2venetoclax 1ofatumumab 1obinutuzumab 1ioflupane 1imetelstat 1ibrutinib 1gossypol acetic acid 1gilteritinib 1fluorocholine 1fluciclovine F-18 1deltacortene 1daratumumab 1aflibercept 1abiraterone 1Temozolomide 1Self-Management 1Quality of Life 1Professional Autonomy 1Paclitaxel 1Oncolytic Virotherapy 1Octreotide 1Mitoxantrone 1Methylene Blue 1Lenalidomide 1Gemtuzumab 1Gemcitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Disease × Octreotide × Clear all
NCT00332969 2017-03-31

Efficacy of Octreotide Treatment in Patients With Primary Inoperable Thymoma

Novartis

Phase 2 Completed
25 enrolled
Thoracic

Disease, Neoplasms, Thymoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡